scholarly journals Preservation of Cerebral Vascular Reactivity by Sodium Channel Inhibition in Acute Prolonged Asphyxic Brain Injury (ABI) in Piglets

1999 ◽  
Vol 45 (6) ◽  
pp. 910-910
Author(s):  
Vladimir Levine ◽  
Massroor Pourcyrous ◽  
Henrietta Bada ◽  
Wenjian Yang ◽  
Sheldon Korones ◽  
...  
1999 ◽  
Vol 45 (4, Part 2 of 2) ◽  
pp. 207A-207A
Author(s):  
Vladimir Levine ◽  
Massroor Pourcyrous ◽  
Henrietta S Bada ◽  
Wenjian Yang ◽  
Sheldon B Korones ◽  
...  

2009 ◽  
Vol 30 (3) ◽  
pp. 628-637 ◽  
Author(s):  
Guoyi Gao ◽  
Yasutaka Oda ◽  
Enoch P Wei ◽  
John T Povlishock

This study examined the effect of posttraumatic hypoxia on cerebral vascular responsivity and axonal damage, while also exploring hypothermia's potential to attenuate these responses. Rats were subjected to impact acceleration injury (IAI) and equipped with cranial windows to assess vascular reactivity to topical acetylcholine, with postmortem analyses using antibodies to amyloid precursor protein to assess axonal damage. Animals were subjected to hypoxia alone, IAI and hypoxia, IAI and hypoxia before induction of moderate hypothermia (33°C), IAI and hypoxia induced during hypothermic intervention, and IAI and hypoxia initiated after hypothermia. Hypoxia alone had no impact on vascular reactivity or axonal damage. Acceleration injury and posttraumatic hypoxia resulted in dramatic axonal damage and altered vascular reactivity. When IAI and hypoxia were followed by hypothermic intervention, no axonal or vascular protection ensued. However, when IAI was followed by hypoxia induced during hypothermia, axonal and vascular protection followed. When this same hypoxic insult followed the use of hypothermia, no benefit ensued. These studies show that early hypoxia and delayed hypoxia exert damaging axonal and vascular consequences. Although this damage is attenuated by hypothermia, this follows only when hypoxia occurs during hypothermia, with no benefit found if the hypoxic insult proceeds or follows hypothermia.


2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Peter Lukacs ◽  
Mátyás C. Földi ◽  
Luca Valánszki ◽  
Emilio Casanova ◽  
Beáta Biri-Kovács ◽  
...  

2000 ◽  
Vol 53 (3) ◽  
pp. 245-254 ◽  
Author(s):  
Péter Bönöczk ◽  
Balázs Gulyás ◽  
Vera Adam-Vizi ◽  
András Nemes ◽  
Egon Kárpáti ◽  
...  

2014 ◽  
Vol 46 ◽  
pp. 749
Author(s):  
Chansol Hurr ◽  
Kiyoung Kim ◽  
Michelle L. Harrison ◽  
Joshua F. Lee ◽  
Kevin M. Christmas ◽  
...  

Climacteric ◽  
2003 ◽  
Vol 6 (3) ◽  
pp. 228-237 ◽  
Author(s):  
C. O. Lund ◽  
L. Nilas ◽  
T. Dalsgaard ◽  
S. H. Pedersen ◽  
B. Ottesen

Author(s):  
Dmytro O Kryshtal ◽  
Daniel Blackwell ◽  
Christian Egly ◽  
Abigail N Smith ◽  
Suzanne M Batiste ◽  
...  

Rationale: The class Ic antiarrhythmic drug flecainide prevents ventricular tachyarrhythmia in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease caused by hyperactive cardiac ryanodine receptor (RyR2) calcium (Ca) release. Although flecainide inhibits single RyR2 channels in vitro, reports have claimed that RyR2 inhibition by flecainide is not relevant for its mechanism of antiarrhythmic action and concluded that sodium channel block alone is responsible for flecainide's efficacy in CPVT. Objective: To determine whether RyR2 block independently contributes to flecainide's efficacy for suppressing spontaneous sarcoplasmic reticulum (SR) Ca release and for preventing ventricular tachycardia in vivo. Methods and Results: We synthesized N-methylated flecainide analogues (QX-FL and NM-FL) and showed that N-methylation reduces flecainide's inhibitory potency on RyR2 channels incorporated into artificial lipid bilayers. N-Methylation did not alter flecainide's inhibitory activity on human cardiac sodium channels expressed in HEK293T cells. Antiarrhythmic efficacy was tested utilizing a calsequestrin knockout (Casq2-/-) CPVT mouse model. In membrane-permeabilized Casq2-/- cardiomyocytes — lacking intact sarcolemma and devoid of sodium channel contribution — flecainide, but not its analogues, suppressed RyR2-mediated Ca release at clinically relevant concentrations. In voltage-clamped, intact Casq2-/- cardiomyocytes pretreated with tetrodotoxin (TTX) to inhibit sodium channels and isolate the effect of flecainide on RyR2, flecainide significantly reduced the frequency of spontaneous SR Ca release, while QX-FL and NM-FL did not. In vivo, flecainide effectively suppressed catecholamine-induced ventricular tachyarrhythmias in Casq2-/- mice, whereas NM-FL had no significant effect on arrhythmia burden, despite comparable sodium channel block. Conclusions: Flecainide remains an effective inhibitor of RyR2-mediated arrhythmogenic Ca release even when cardiac sodium channels are blocked. In mice with CPVT, sodium channel block alone did not prevent ventricular tachycardia. Hence, RyR2 channel inhibition likely constitutes the principal mechanism of antiarrhythmic action of flecainide in CPVT.


Sign in / Sign up

Export Citation Format

Share Document